• English
  • Korean
  • Chinese
市場調査レポート - 235126

世界の体外診断検査市場

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition

発行 Kalorama Information
出版日 ページ情報 英文 1200 Pages
電子版即納可
価格
世界の体外診断検査市場 The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition
出版日: 2014年08月13日 ページ情報: 英文 1200 Pages
担当者のコメント
1997年に第1版の発売以来、約2年毎にアップデート版を発行し、2014年8月に第9版を発行、発売開始致しました。17年間にわたる世界の体外診断市場リサーチを行なうカロラマインフォメーション社の当調査レポートは、今やIVD調査のグローバルスタンダードとも言え、世界中のIVD関連企業が活用するベストセラーレポートです。
概要

当レポートでは、世界の体外診断(IVD)検査市場について調査し、主要な臨床ラボ検査のセグメント別分析を提供しており、セグメント別の市場規模、予測、シェアおよび地域別分析、技術開発、規制・医療費償還問題、臨床ケアおよびビジネス環境の変化動向、主要企業のプロファイルをまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 世界の体外診断(IVD)市場概要

  • 背景
  • 世界の人口および疾病統計
  • 市場促進因子としての新興市場
  • 世界のIVD市場セグメントおよびIVD市場の発展
    • 特定国の情報
    • 米国:流動的な世界
    • 日本
    • 欧州:マイナス成長 - 緊縮財政の影響
    • 中国
    • インド
    • ブラジル
    • ロシア
    • カナダ

第4章 動向・革新

  • 背景
  • ITがサンプルの分析を可能に
  • オミクスとビッグデータ
  • シーケンシングがクリニックに移行
  • オーダーメイドの高効果を示す治療薬「Precision Medicine」の進歩と障壁
  • LOCがモバイルヘルス(mヘルス)を可能に

第5章 ポイントオブケア(POC)検査

  • 概要
  • 大腸癌スクリーニング
  • 主なPOC検査企業
  • 糖尿病検査:血糖モニタリング

第6章 コアラボ

  • コアラボの概要
  • 化学検査の概要
  • ラボオートメーション
  • 市場分析
  • コアラボの商業的見通し

第7章 免疫測定

  • 免疫測定の概要
  • 発展を続ける免疫測定技術
  • コアラボにおける免疫測定
  • スペシャルトピック:代謝産物検査
  • 市場分析
  • 主要サプライヤーおよび成長の可能性
  • アッセイセグメント
  • ポイントオブケアOTCおよび専門的用途
  • 患者による自己検査(OTC)
  • 免疫測定の商業的見通し

第8章 分子アッセイ

  • 概要
  • 先進分子検査・技術
  • デジタルPCR
  • エクソーム
  • 主要企業

第9章 血液学

  • 血液学の概要
  • デジタル画像分析
  • デジタル進化
  • 分散血液検査
  • 市場分析:主要サプライヤー
  • 血液検査の商業的見通し

第10章 凝析

  • 凝固および免疫血液検査の概要
  • 遺伝学および個別化医療
  • 市場分析
  • ラボ型検査
  • ハイパー凝血異常の遺伝子マーカー
  • 分散凝固検査:専門的用途
  • 分散凝固検査:OTC
  • 血小板検査
  • 主要サプライヤー
  • 凝固検査の商業的見通し

第11章 微生物学およびウィルス学

  • 概要
  • 特定トピック
  • いくつかの疾病のデータ
  • 新しい病気の脅威
  • 抗菌薬耐性
  • 幻想ではない質量分析法
  • 敗血症血清学
  • 市場分析
  • サプライヤー
  • 微生物同定および抗菌薬感受性検査
  • 血液培養
  • 迅速検査
  • 免疫測定:ラボベース
  • 免疫測定:迅速
  • 市場分析
  • 微生物/ウィルス検査の商業的見通し

第12章 血液バンクサービス

  • 概要
  • 血液バンクの大改革
  • 血液管理:すべての輸血はいい薬?
  • 病原菌の警戒
  • 血小板安全性
  • 血液型判定
  • 免疫測定
  • 核酸検査(NAT)
  • 血液バンクの商業的見通し

第13章 組織学および細胞学

  • 概要
  • 特定トピック
  • 先進分析ソリューション
  • HPVはコアラボに
  • 市場分析
  • 免疫組織化学およびIn Situハイブリダイゼーション
  • ファーマコダイアグノスティクスの組織学
  • デジタル画像
  • 循環腫瘍細胞
  • フローサイトメトリー
  • 組織および細胞検査の商業的見通し

第14章 企業プロファイル:トップティア

第15章 企業プロファイル:第2ティア

第16章 企業プロファイル:血液バンク専門企業

第17章 企業プロファイル:凝析専門企業

第18章 企業プロファイル:コアラボおよびその他の企業

第19章 企業プロファイル:CTC検査プロバイダー

第20章 企業プロファイル:糖尿病専門企業

第21章 企業プロファイル:細胞学(細胞分析)専門企業

第22章 企業プロファイル:組織学専門企業

第23章 企業プロファイル:免疫測定専門企業

第24章 企業プロファイル:IT専門企業

第25章 企業プロファイル:微生物学専門企業

第26章 企業プロファイル:分子検査専門企業

第27章 企業プロファイル:POC専門企業

第28章 企業プロファイル:出生前診断サービスプロバイダー

第29章 企業プロファイル:検査サービスプロバイダー

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

In nine best-selling editions, Shara Rosen (MBA, RT), has created authoritative market estimates and forecasted growth models for in vitro diagnostic (IVD) testing products throughout the world. This single volume covers the entirety of the clinical testing market and all of its segments, providing customers with a tremendous value.

Used by Top IVD Companies For Business Planning.

This year, Kalorama has published its ninth edition of this informative volume based on the market events of 2013 and early 2014. New entrants, new technologies have entered the stage and all important events are cataloged in this report. The idea behind Kalorama's unique report is that the entire market can be captured in one volume. Published every two years, this volume includes market estimates for 2013 base year and forecasts to 2018 for the most important aspects of all of the major segments of clinical lab testing, including:

  • Core Lab (General Chemistries, Workstations, Analyzers Blood Gases, Urinalysis, Critical Care)
  • Point of Care (POC) , (Professional and Self-Testing, Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other)
  • Histology and Cytology (Pap, ISH, IHC, HPV)
  • Lab-based Infectious Disease Immunoassays, by Test (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
  • Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
  • Hematology
  • Molecular Test Sales, Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others
  • Lab-based Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D)
  • Coagulation (Lab-Based, POC, Genetic Markers)
  • Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
  • Blood Banking (Grouping, Immunoassay Screens, NAT Screens)

The Worldwide Market for In Vitro Diagnostic Tests is a testament to the Kalorama methodology. It is the result of months of painstaking work by an IVD industry veteran, who has tracked hundreds of companies for developments, trends and financial results. This research is compiled along with the opinion, observations and insights of industry experts to produce an unparalleled vision of the industry as it is in 2014. The report includes data in a sizeable number of IVD segments and detailed discussion of the trends that are impacting the industry. The report also provides a realistic forecast five years into the future for companies already participating in or considering entry into this growing industry.

Independent Perspective. Authoritative Coverage.

At 1200 pages, this is the most comprehensive report on the in vitro diagnostic industry available. No surprise that it has been called the 'Bible of the IVD Industry' by past users of the report. Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. This edition greatly expands coverage of the field and tracks the most important developments.

Understand areas of the market that might not be available in your company's internal resources. View the industry from an independent point of view. Learn about competitors in a way that may be invisible to internal personnel. Know the market players - your potential partners, your existing or potential competitors, in proper context. Save countless hours of staff time and other research expenses with the authoritative guide for IVD market estimates and forecasts.

Worldwide Coverage, Including Emerging Markets.

From the first edition, this report has been intended to create a global picture for readers. Clinical testing is a worldwide business. This has always been true, but today emerging markets are part of the growth strategy of companies large and small. Kalorama has adjusted to these industry trends with enhanced geographic segmentation. While the US is a large healthcare market, many of the most interesting opportunities for companies are occurring in emerging markets.

As part of its coverage, the report breaks down the entire IVD market for the following regions:

  • North America
  • Europe (with total IVD market sizes for EU countries)
  • Asia (China, Japan, India)
  • Latin America
  • Rest of World

Not Just "What" Happened in the Industry, But "Why?"

The report does not merely report figures absent context. It describes the competitive workings of the diagnostics industry, combining a competitor, product, regulatory and payor decision analysis. In addition to providing authoritative market estimates for IVD market segments, this unique report seeks to explain why market events are occurring. The report delves into fast- breaking trends in in vitro diagnostics and distinguishes between company PR and actual market reality.

As part of its coverage, the following trends are detailed in the report:

  • Sample to Insight: IT Makes It Possible
  • The Lure of IVD - Companies Mix and Match
  • Distribution Agreements
  • Emerging Market Growth
  • Licenses and Collaboration Agreements
  • Test Services Commercialization
  • Top Suppliers and Niche Players
  • Selected Test Innovations from Non-Commercial Facilities
  • Sequencing Moves To The Clinic
  • LDTs
  • Personalized Precision Medicine Advances and Barriers
  • LOCs Enable Mobile Health (mHealth)
  • Digital PCR
  • Exomes
  • Omics and BIG Data

Superior Company Profiling - Understand How Companies Rank and Where They Compete.

The report contains detailed profiles of the top players in IVD. Profiling in this report describes the developments in each significant division of their business. A number of secondary players are also extensively profiled, as well as specialty companies with expertise in one testing area.

  • Abbott Diagnostics
  • Alere Inc.
  • Arkray
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company (BD)
  • bioMérieux Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Ortho Clinical Diagnostics (OCD)
  • QIAGEN N.V.
  • Siemens Healthcare Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Affymetrix Inc.
  • Cepheid
  • Eiken Chemical Co., Ltd
  • ERBA Diagnostics, Inc.
  • DiaSorin S.p.A
  • Fujirebio Diagnostics, Inc.
  • Illumina
  • LabCorp
  • Luminex Corporation
  • Menarini Diagnostics
  • Myriad Genetics
  • PerkinElmer, Inc. (PE)
  • Quest Diagnostics
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • TOSOH Corporation
  • Wako Pure Chemical Industries
  • And hundreds of other companies...

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Data for the in vitro diagnostic market are presented in U.S. dollar market size for categories of tests, and for specific analytes where possible. The dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the IVD industry.

Additional Information

New Report Says In Vitro Diagnostic Market Reaches 54.6Billion

NEW YORK, N.Y. - The world marketfor diagnostics is estimated at $54.6 billion in 2013, according to KaloramaInformation. The market is expected to grow 4% annually and reach $65billion by 2018. This includes all laboratory and hospital-basedproducts, and OTC product sales. Kalorama revealed the market estimatesin its biennial survey of the IVD industry, The Worldwide Market for In Vitro DiagnosticTests, 9th Edition.

New technology is leading thecharge, according to Kalorama. Diagnostic laboratory technology haschanged dramatically in the past few years, due to the publication of the humangenome project and advances in functional genomics, bioinformatics,miniaturization and microelectronics.

"Not three years ago it would havebeen almost inconceivable to see research technologies such as genomesequencing and mass spectroscopy play a pivotal role in improving labmedicine," said Shara Rosen, Kalorama's lead diagnostic analyst and the authorof the report. "Their influence is felt in personalized medicine,inherited diseases, pathogen detection, antibiotic resistance testing, bloodbanking and much more to come."

According to the report, thisphenomenon has seen the major vendors of these technologies enter the IVDmarket. Life Technologies, Illumina, Affymetrix, Bruker Daltonics,PerkinElmer/Caliper and others have all launched clinical tests and testservices.

Commentary on LDT Regulatory changes

The 8th edition of this report published in 2012 discussed the possible regulation of lab developed tests (LDTs). Well in 2014, the possible is a reality. In the beginning .... September 2006, the FDA issued a draft guidance on analyte specific reagents (ASRs), which are commercially available reagents used in lab developed tests (LDTs). The FDA decided to use enforcement discretion and excluded laboratory-developed tests from the ASR rule based on confidence in a high-complexity laboratory's ability to use them.

LDTs are developed within the laboratory and do not currently require FDA clearance. They are currently regulated under CLIA as highly complex tests and thus are subject to in-house validation and cGMP quality documentation requirements.

August 1, 2014, the FDA announced plans to implement a risk-based regulation of laboratory-developed tests over the course of nine years. The FDA also said it plans to release its draft guidance in 60 days. The FDA's announcement comes out at a time when the agency has come under increasing pressure from congressional and federal advisory committees, consumer groups and the industry to expand its oversight of in-house developed testing. The FDA announcement stated that LDTs have become an intrinsic part of personalized medicine and that inaccurate test results could cause patients to seek unnecessary treatment, or delay and sometimes forgo treatment altogether. Further the policy change "demonstrates the agency's commitment to personalized medicine, which depends on accurate and reliable tests to get the right treatment to the right patient."

The statement also stated that the FDA would implement the regulations over a nine-year period and would focus on tests where a wrong result would pose the highest risk for patients. It also said it would exempt tests for which there is no approved alternative and tests for rare diseases.

The FDA says it intends to require pre-market review for higher-risk LDTs, such as those that have the same intended use as FDA-approved or cleared companion diagnostics currently on the market. The draft guidance also proposed that LDTs would be classified as Class I, II, or III depending on risk. The agency will first focus on high-risk devices that have the same intended use as cleared or approved companion diagnostics.

It is expected that the classification may take the form of a proposal submitted by the American College of Medical Genetics and Genomics. In 3013, the American College of Medical Genetics and Genomics (ACMG) released a framework to standardize risk classification of laboratory developed tests (LDTs) for inherited conditions. The approach represents a regulatory context that the group hopes will be used to assist federal agencies and policymakers. The ACMG presented risk-based classification that aligns risk with the medical decisions made based on the test results and how an incorrect result or interpretation might impact patients.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Doing More with Less
  • Scope and Methodology
  • Size and Growth of the Market
  • Market Trends

CHAPTER TWO: INTRODUCTION

  • Background
    • Report Design
  • Lab Medicine Disciplines and Applications
  • Market Analysis of IVD Market Segments
  • The Lure of IVD - Companies Mix and Match
    • Distribution Agreements
    • Licenses and Collaboration Agreements
  • Test Services
  • Top Suppliers and Niche Players
  • Selected Test Innovations from Non-Commercial Facilities
    • Baylor Research Institute, Dallas, TX
    • Boston University, Boston, MA
    • Brown University, Providence, RI
    • California Institute of Technology, Pasadena, CA
    • California NanoSystems Institute
    • Cedars Sinai Medical Center, Los Angeles, CA
    • Cleveland Clinic, Cleveland, OH
    • Duke University, Durham, NC
    • Hartford Hospital, Hartford, CT
    • Johns Hopkins University School of Medicine, Baltimore, MD
    • MedStar Washington Hospital Center, Washington, DC
    • Mount Sinai's Samuel Lunenfeld Research Institute, Toronto, ON
    • Northeastern University, Boston, MA
    • Peking University, Beijing, China
    • Queensland Institute of Medical Research, Brisbane, Australia
    • Schneider Children's Medical Center of Israel, Tel Aviv, Israel
    • Stockholm University, Sweden
    • Tokyo Medical and Dental University, Tokyo, Japan
    • University of British Columbia, Vancouver, BC
    • University of California, Davis, CA
    • University of California, Urvine, Urvine, CA
    • University of Cincinnati, Cincinnati, OH
    • University of Cologne, Cologne, Germany
    • University of Washington, Seattle, WA
    • Vanderbilt University, Nashville, TN
    • Weill Cornell Medical College, New York, NY
    • Yonsei University Health System, Seoul, S. Korea

CHAPTER THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS

  • Background
  • Population and Disease Demographics, Worldwide
  • Emerging Markets as a Market Driver
  • World Segments of the IVD Market and IVD Market Evolution
    • Specific Country Information
    • The United States of America - a World in Flux
    • Japan
    • Europe: Negative Growth - Effects of Austerity
    • China
    • India
    • Brazil
    • Russia
    • Canada

CHAPTER FOUR: TRENDS AND INNOVATION

  • Background
  • IT Enables Sample to Insight
  • Omics and BIG Data
  • Sequencing Moves to the Clinic
  • Personalized Precision Medicine Advances and Barriers
  • LOCs Enable Mobile Health (mHealth)

CHAPTER FIVE: POINT-OF-CARE TESTS

  • Overview
    • Professional POC
    • OTC Self Testing
  • Colon Cancer Screening
  • The Major POC Test Players
  • Diabetes Testing - Blood Glucose Monitoring
    • Glucose Market Shakeup
    • Diabetes Market Analysis
    • Blood Glucose Self-Testing
    • Continuous Self-Testing
    • Blood Glucose Testing by Professionals
    • New Technologies
    • Diabetes Testing - Glycated Hemoglobin
    • The Genetics of Diabetes

CHAPTER SIX: THE CORE LAB

  • Core Lab Overview
  • Overview of Chemistry Tests
  • Lab Automation
  • Market Analysis
    • Lab-based Chemistries
    • Critical Care Analysis
    • User Apps
    • Urinalysis
  • The Commercial Outlook for Chemistry Tests

CHAPTER SEVEN: IMMUNOASSAYS

  • Overview of Immunoassays
  • Immunoassay Technology Continues to Evolve
  • Immunoassays in the Core Lab
  • Special Topic - Metabolite Testing
  • Market Analysis
  • Leading Suppliers and Growth Potential
  • Assay Segments
    • Thyroid Function
    • Therapeutic Drug Tests
    • Anemia
    • Toxicology/DAU
    • Allergy
    • Proteins
    • Vitamin D
    • Tumor Markers
    • Cardiac Markers
    • Autoimmune
    • Diabetes
    • Transplant Management
    • Women's Health
    • Gastrointestinal Disorders
    • Miscellaneous
  • Point-of-Care OTC and Professional Use
  • Patient Self-Tests (OTC)
    • Pregnancy Testing
    • Cardiovascular Diagnostics
    • Drugs of Abuse/Therapeutic Drug Monitoring
  • The Commercial Outlook for Immunoassays

CHAPTER EIGHT: MOLECULAR ASSAYS

  • Overview
  • Advanced Molecular Tests and Technologies
  • Digital PCR
  • Exomes
  • Major Players
    • Market Analysis
    • Oncology
    • Inherited Diseases
    • Prenatal Analysis
    • Tissue Typing
    • The Commercial Outlook for Molecular Tests

CHAPTER NINE: Hematology

  • Overview of Hematology
  • Digital Image Analysis
  • Digital Evolution
  • Decentralized Hematology Testing
    • Hemoglobin/Hematocrit at the POC
  • Market Analysis: Leading Suppliers
  • The Commercial Outlook for Hematology Tests

CHAPTER TEN: COAGULATION

  • Overview of Coagulation and Immunohematology Tests
  • Genetics and Personalized Medicine
  • Warfarin
  • Plavix
  • Market Analysis
  • Lab-based Testing
  • Genetic Markers of Hypercoagulopathies
  • Decentralized Coagulation Testing - Professional Use
  • Decentralized Coagulation Testing - OTC
  • Platelet Testing
  • Leading Suppliers
  • The Commercial Market for Coagulation Tests

CHAPTER ELEVEN: MICROBIOLOGY AND VIROLOGY

  • Overview
  • Special Topics
  • Some Disease Facts
  • Emerging Disease Threats
  • Antimicrobial Drug Resistance
  • Mass Spectrometry Not a Pipedream
  • Sepsis Serology
  • Market Analysis
  • Supplies
  • Microbial Identification and Antimicrobial Sensitivity Tests
  • Blood Culture
  • Rapid Tests
  • Immunoassays - Lab-based
  • Immunoassays - Rapid
  • Molecular Tests
  • The Commercial Outlook for Microbiology / Virology Tests

CHAPTER TWELVE: BLOOD BANKING SERVICES

  • Overview
  • Blood Banking Gets a Shakeup
  • Blood Management - Are All These Transfusions Good Medicine?
  • Pathogen Alerts
  • Platelet Safety
  • Market Analysis
  • Blood Grouping and Typing
  • Immunoassays
  • Nucleic Acid Testing (NAT)
  • The Commercial Outlook for Blood Banking
  • chapter thirteen
  • Histology and Cytology
  • Overview
  • Special Topics
  • Advanced Analysis Solutions
  • HPV Goes Core Lab
  • Market Analysis

CHAPTER THIRTEEN: HISTOLOGY/CYTOLOGY

  • Immunohistochemistry and In Situ Hybridization
  • Pharmacodiagnostic Histology
  • Digital Imaging
  • Circulating Tumor Cells
  • Flow Cytometry
  • The Commercial Outlook for Histology and Cytology Tests

CHAPTER FOURTEEN: COMPANY PROFILES: THE TOP TIER

  • Abbott Diagnostics
    • Recent Revenue History
    • Highlights
    • Core Lab
    • Immunoassays
    • Molecular
    • Hematology
    • Histology
    • Blood Bank
    • Point of Care
    • Diabetes
    • IntelligentMDx Alliance
    • PLEX-ID
  • Alere Inc.
    • Recent Revenue History
    • HIV
    • Lab-based
    • Blood Gases
    • Hematology
    • Microbiology
    • Toxicology
    • Cardiology
    • Mail Order Glucose Meters
    • Molecular
    • Alere Medical India
  • Arkray
    • Recent Revenue History
    • Molecular
    • Beckman Coulter, Inc. / Danaher
    • Recent Revenue History
    • Core Lab
    • Hematology
    • Immunoassays
    • Histology
    • Flow Cytometry
    • Molecular
    • Lab Services
  • Becton, Dickinson and Company (BD)
    • Recent Revenue History:
    • Initiatives
    • Traditional Microbiology
    • Blood Culture
    • The BD MAX Enterprise
    • HPV
    • Veritor System - Immunoassays
    • Continuous Blood Glucose
    • Flow Cytometry
    • Histology
    • Mass Spectrometry
  • bioMérieux Inc.
    • Recent Revenue History
    • Expansion
    • Immunoassays
    • Blood Culture
    • Molecular Strategy
    • Mass Spectrometry
  • Bio-Rad Laboratories, Inc.
    • Recent Revenue History
    • Controls
    • Digital PCR
    • Blood Bank
    • Flow Cytometry
    • Lab Automation
  • Danaher Corporation
    • Recent Revenue History
  • Hologic, Inc.
    • Recent Revenue History
    • Product News
    • Blood Bank
    • Quest Contract
    • The Gen-Probe Business
    • Panther System
    • Instrumentation Laboratory (IL)
    • Recent Revenue History
    • New Products
    • Direct Sales
  • Ortho Clinical Diagnostics (OCD)
    • Recent Revenue History
    • Blood Bank
  • QIAGEN N.V.
    • Recent Revenue History
    • Personalized Healthcare
    • TB Testing
    • HPV
    • Oncology
    • Automation for the Future
    • Rotor-Gene Q
    • Exosomes
    • Sequencing
    • Information Technology
    • Point of Care
    • Collaborations
    • Radiometer A/S
    • Recent Revenue History
    • Immunoassays
    • Hemocue AB
  • Roche Diagnostics
    • Recent Revenue History
    • Reorganization
    • The PCR Enterprise
    • Core Lab
    • Molecular Core Lab IT
    • Immunoassays
    • Diabetes
    • Point of Care
    • Coagulation
    • HPV
    • Blood Bank
    • Liquid Biopsy
    • Molecular
    • Sequencing
    • Siemens Healthcare Diagnostics
    • Core Lab
    • Immunoassays
    • Hematology
    • Microbiology
    • Point of Care
    • Coagulation
    • Histology
    • Urinalysis
    • Critical Care
    • Molecular
    • Companion Diagnostics
    • Sequencing
  • Sysmex Corporation
    • Recent Revenue History
    • Hematology
    • Coagulation
    • Clinical Chemistry
    • Inostics GmbH
    • Intraoperative Test
    • Flow Cytometry
  • Thermo Fisher Scientific Inc.
    • Recent Revenue History
    • Sepsis
    • Histology
    • Allergy
    • Therapeutic Drug Monitoring
    • Mass Spectrometry
    • Microbiology
  • Werfen Group S.A.

Company Profiles: The Second Tier

  • Affymetrix Inc.
    • Recent Revenue History
  • Agilent Technologies
    • Recent Revenue History
    • Arrays
    • Sample Management
    • Mass Spectrometry
    • Expansion
  • Cepheid
    • Recent Revenue History:
    • Hospital Acquired Infections (HAI)
    • TB
    • Infectious Diseases
    • Oncology
  • Eiken Chemical Co., Ltd
    • Recent Revenue History
  • ERBA Diagnostics, Inc.
    • Recent Revenue History
  • ERBA Mannheim
    • DiaSorin S.p.A.
  • Recent Revenue History
  • Molecular
  • Immunoassays
  • Fujirebio Diagnostics, Inc.
    • Recent Revenue History
    • Molecular
  • Illumina
    • Recent Revenue History:
    • Sequencing
    • Cytogenetics
    • Prenatal Testing
    • CLIA Lab Service
    • Nanopore Sequencing
    • Sample to Insight
    • IP Situation
  • LabCorp, Laboratory Corporation of America
    • Recent Revenue History
    • Collaborations
    • BRCA Saga
  • Life Technologies Corporation
    • Recent Revenue History
    • Life Technologies as an IVD Company
    • Partnerships Worldwide
    • Life and Quidel Develop Diagnostics on the Fast Dx
    • Sepsis
    • HIV
    • Emerging Pathogens
    • Bacterial Typing
    • Personalized Medicine
    • Instrumentation and Applications
  • Luminex Corporation
    • Recent Revenue History:
    • Business Expansion
    • MAGPIX Multiplexing
    • Next Generation NxTag
    • Product News
  • Menarini Diagnostics
    • Recent Revenue History:
  • Myriad Genetics
    • Recent Revenue History:
    • Product News
    • The U.S. Market
    • IP Update
  • PerkinElmer, Inc. (PE)
    • Recent Revenue History:
    • Newborn Testing
    • Prenatal Testing
    • Histology
    • Sequencing
    • Mass Spectrometry
    • Information Technology
    • China
  • Quest Diagnostics
    • Recent Revenue History:
  • Quidel Corporation
    • Recent Revenue History:
    • Acquisitions
    • Point of Care
    • Immunoassays
    • Molecular
    • Savanna (formerly Wildcat)
  • Randox Laboratories Ltd.
    • Recent Revenue History:
    • Controls
    • Immunoassays
    • Molecular
  • TOSOH Corporation
    • Recent Revenue History:
    • Immunoassays
    • Transasia Bio-Medicals Ltd.
    • Recent Revenue History
  • Trinity Biotech plc
    • Recent Revenue History:
    • Product News
  • Wako Pure Chemical Industries, Ltd.
    • Recent Revenue History:

SIXTEEN: COMPANY PROFILES: BLOOD BANK SPECIALISTS

  • Cerus Corporation
  • Grifols
  • Haemonetics Corporation
  • Immucor, Inc.
  • Immunetics Inc.
  • Novartis Molecular Diagnostics
  • International Programs
  • Quotient Limited
  • Terumo BCT
  • Verax Biomedical Inc.

SEVENTEEN: COMPANY PROFILES: COAGULATION SPECIALISTS

  • Accriva Diagnostics
  • Atherotech Diagnostics Lab
  • Diagnostica Stago, S.A.S.
  • Gamma Therapeutics, Inc.
  • Microvisk Technologies

EIGHTEEN: COMPANY PROFILES: CORE LAB AND OTHER COMPANIES

  • Elektronika Kft
  • AB SCIEX Pte Ltd.
  • Bruker BioSciences Corporation
  • Diatron MI Plc
  • EliTech Group S.A.S.
  • IRIS International, Inc.
  • Medica Corporation
  • MedTest DX
  • Mindray Medical International Limited
  • Nova Biomedical

NINETEEN: COMPANY PROFILES: CTC TEST PROVIDERSAbnova

  • AdnaGen AG
  • Angle plc
  • ApoCell, Inc.
  • Biocept, Inc.
  • Clearbridge BioMedics
  • Cynvenio Biosystems, Inc.
  • Epic Sciences Inc.
  • Fluxion Biosciences, Inc.
  • Icellate AB
  • ProKyma Technologies
  • RareCyte, Inc.
  • ScreenCell
  • Veridex, LLC
  • WaveSense LLC

TWENTY: COMPANY PROFILES: DIABETES SPECIALISTS

  • AgaMatrix, Inc.
  • ALR Technologies Inc.
  • Animas Corporation
  • Bayer Diabetes Care
  • DexCom, Inc.
  • Echo Therapeutics, Inc.
  • Entra Health Systems
  • iHealth Lab Inc.
  • Infopia Co Ltd
  • Insulet Corporation
  • U.S. Medicare Effects
  • Integrity Applications Inc.
  • LabStyle Innovations Corp.
  • Lifescan Inc.
  • IP Issues
  • Medtronic Inc.
  • Newomics Inc.
  • Prodigy Diabetes Care, LLC
  • Sanofi Diabetes
  • Senseonics, Incorporated
  • Tandem Diabetes Care, Inc.
  • TelCare Inc.

TWENTY-ONE: COMPANY PROFILES: HEMATOLOGY (CELL ANALYSIS) SPECIALISTS

  • CellaVision AB
  • Constitution Medical, Inc.
  • DVS Sciences, Inc.
  • Horiba Medical
  • OrSense Ltd.
  • Partec GmbH

Twenty-Two: Company Profiles: Histopathology Specialists

  • Advanced Cell Diagnostics (ACD)
  • Amoy Diagnostics Co. Ltd.
  • Applied Spectral Imaging Inc. (ASI)
  • Biocare Medical, LLC
  • Biodis Biotechnology
  • BioMarker Strategies
  • BioView Ltd.
  • Dako A/S
  • Definiens
  • DxTerity Diagnostics Inc.
  • Leica Biosystems
  • Norchip
  • Ventana Medical Systems Inc.

TWENTY-THREE: COMPANY PROFILES: IMMUNOASSAY SPECIALISTS

  • ALPCO Diagnostics
  • BG Medicine, Inc.
  • Biohit Oyj
  • Market Expansion
  • Corgenix Medical Corporation
  • Critical Diagnostics
  • Diazyme Laboratories
  • Euro Diagnostica AB
  • Genalyte Inc.
  • Gold Standard Diagnostics
  • INOVA Diagnostics, Inc.
  • Matrix-Bio Inc.
  • Oasis Diagnostics Corporation
  • OPKO Diagnostics
  • Pronota NV
  • Quanterix Corporation
  • Tests in Development
  • Response Biomedical Corp.
  • Sera Prognostics, Inc.

TWENTY-FOUR: COMPANY PROFILES: INFORMATION TECHNOLOGY SPECIALISTS

  • Cartagenia
  • Cerner Corp.
  • CLC bio
  • CollabRx Inc.
  • ConnectedHealth Pte. Ltd.
  • IBM Healthcare
  • Intel Corporation
  • Kaiser Permanente
  • MediSapiens Ltd.
  • Personalis Inc.

TWENTY-FIVE: COMPANY PROFILES: MICROBIOLOGY SPECIALISTS

  • AdvanDx, Inc.
  • Co-Diagnostics HBDC
  • Copan Diagnostics Inc.
  • Curetis AG
  • DxNA, LLC
  • Enigma Diagnostics Limited
  • Epistem Holdings plc
  • Focus Diagnostics, Inc.
  • Great Basin Scientific, Inc.
  • Hain Lifescience GmbH
  • Hutman Diagnostics AG
  • Immunexpress Group
  • InBios International, Inc.
  • Intelligent Medical Devices, Inc. (IMDx)
  • Laboratorios CONDA
  • Liofilchem s.r.l.
  • Lophius Biosciences GmbH
  • Lumora
  • MAST GROUP Ltd.
  • ID/AST
  • Immunoassays
  • Molecular
  • MBio Diagnostics, Inc.
  • Meridian Bioscience, Inc.
  • Immunoassays
  • illumigene Molecular
  • Meridian Life Science
  • Miacom Diagnostics GmbH
  • Mobidiag Ltd
  • Nanosphere, Inc.
  • Pathogenica
  • Seegene, Inc.

TWENTY-SIX: COMPANY PROFILES: MOLECULAR TEST SPECIALISTS

  • Amoy Diagnostics Co. Ltd.
  • Asuragen Inc.
  • BGI Projects
  • Biocartis SA
  • Idylla News
  • Biofortuna Ltd.
  • DiaCarta Inc.
  • Enzo Biochem Inc.
  • Epigenomics
  • Exosome Diagnostics
  • Genia Technologies Inc.
  • GenMark Diagnostics
  • HTG Molecular Diagnostics
  • IncellDx, Inc.
  • Inform Genomics
  • Nanostring Technologies, Inc.
  • QuantuMDx Group Limited
  • RainDance Technologies, Inc.
  • Selventa
  • TessArae, LLC
  • TrovaGene, Inc.

TWENTY-SEVEN: COMPANY PROFILES: POINT OF CARE TEST SPECIALISTS

  • 1st Health Products Ltd.,
  • Abaxis, Inc.
  • Aerocrine AB
  • Arbor Vita Corporation
  • Atomo Diagnostics
  • bioLytical Laboratories
  • Chembio Diagnostic Systems, Inc.
  • Counsyl Consumer
  • DiAssess Inc
  • EKF Diagnostics Holdings Plc
  • Gentle Laboratories
  • GlysBy s.n.c.
  • IntraMed Diagnostics, LLC
  • LeucoDx
  • Luoxis Diagnostics Inc.
  • Maxim Biomedical, Inc.
  • MedMira Inc.
  • Mode Diagnostics, Ltd
  • NEC Corporation
  • OraSure Technologies, Inc.
  • Pixie Scientific
  • Radisens Diagnostics Ltd.
  • Samsung Healthcare
  • STDcheck.com
  • UDoTest

TWENTY-EIGHT: COMPANY PROFILES: PRENATAL TEST SERVICE PROVIDERS

  • Ariosa Diagnostics, Inc.
  • Berry Genomics Co. Ltd
  • CellScape Corporation
  • GenePeeks, Inc.
  • Genomed AG
  • Good Start Genetics, Inc.
  • Illumina
  • INEX (Innovations Exchange Pte Ltd)
  • Kellbenx Inc.
  • Natera
  • NIPD Genetics Ltd
  • Sequenom Inc.
  • Sera Prognostics, Inc.

TWENTY-NINE: COMPANY PROFILES: TEST SERVICE PROVIDERS

  • 23andMe
  • Adaptive Biotechnologies Corporation
  • Agendia BV
  • Ambry Genetics
  • ARUP Laboratories
  • Assurex Health
  • Athena Diagnostics
  • BioReference Laboratories, Inc. (BRLI)
  • Boulder Diagnostics Inc.
  • Cancer Genetics, Inc. (CGI)
  • CardioDx, Inc.
  • Clarient Diagnostic Services, Inc.
  • Combimatrix Corp.
  • Diatherix Laboratories Inc.
  • Genomic Health, Inc.
  • Imugen Inc.
  • LipoScience Inc.
  • Mayo Medical Laboratories
  • MDxHealth SA
  • Medical Diagnostic Laboratories L.L.C. (MDL)
  • Metabolistics Inc.
  • Metabolon, Inc.
  • Metamark Genetics Inc.
  • OncoPlexDx
  • Rosetta Genomics Ltd.
  • Sengenics International Pte Ltd
  • Veracyte, Inc.

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Table 1-1: Exchange Rate Fluctuations, 2009-2013
  • Table 1-2: Worldwide In Vitro Diagnostic Reagent Sales by Market Segment 2013-2018 (Clinical Chemistry, Immunoassays - non isotopic, Infectious Diseases, Other Immunos, Blood Bank Screening, Diabetes HbA1c, Lab, Hematology, Microbiology (ID/AST), Microbiology - molecular, Radioimmunoassays, Coagulation, Histology/Cytology, HPV - molecular, Nucleic Acid Assays, Blood Grouping/Typing, Blood Bank Molecular, Flow Cytometry, Circulating Tumor Cells, POC - OTC diabetes, POC - OTC other, POC - Professional/Hospital)

TWO: INTRODUCTION

  • Table 2-1: Worldwide In Vitro Diagnostic Sales by Product Market (Clinical Chemistry, Immunoassays - non isotopic, Infectious Diseases, Other Immunos, Blood Bank Screening, Diabetes HbA1c, Lab, Hematology, Microbiology (ID/AST), Microbiology - molecular, Radioimmunoassays, Coagulation, Histology/Cytology, HPV - molecular, Nucleic Acid Assays, Blood Grouping/Typing, Blood Bank Molecular, Flow Cytometry, Circulating Tumor Cells, POC - OTC diabetes, POC - OTC other, POC - Professional/Hospital) 2013-2018
  • Table 2-2: Selected Diagnostics Industry Acquisitions, 2012 and 2013
  • Table 2-3: Selected Diagnostics Industry Distribution Agreements, 2012 and 2013
  • Table 2-4: Selected IVD Licensing Agreements, 2012-2013
  • Table 2-5: Selected IVD Collaboration Agreements, 2012-2013
  • Table 2-6: New IVD Company Developments, 2012-2013
  • Table 2-7: Selected Test Services, Sales 2009-2013
  • Table 2-8: Lab Market Segmentation (Hospital Labs, Independent Labs, Physician Office Labs), Worldwide, 2013
  • Table 2-9: Revenues for a Selection of U.S.-based Reference Labs, 2009-2013
  • Table 2-10: Selected CLIA-certified Labs Established in 2012 and 2013
  • Table 2-11: Selected International Lab Developments, 2013
  • Table 2-12: Revenues of Selected Top IVD Companies, 2009-2013
  • Table 2-13: Revenues of Selected Niche Players, 2009-2013
  • Table 2-14: Selected IVD Market Laggards, 2012-2014

THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS

  • Table 3-1: World Population Distribution, August 2014
  • Table 3-2: Selected Disease Statistics, Worldwide
  • Table 3-3: Elderly Support Ratio in Selected Countries (2050)
  • Table 3-4: Available Market Data, 2013
  • Table 3-5: Healthcare Spending as a % of GDP Growth, Selected Developed Countries
  • Table 3-6: Healthcare Spending as a % of GDP Growth, Selected Emerging Markets
  • Table 3-7: Worldwide In Vitro Diagnostic Reagent Sales by Country/Region 2013-2018
  • Table 3-8: European Union (EU14) IVD Sales by Country 2012

FOUR: TRENDS AND INNOVATION

  • Table 4-1: Selected IT Enabled Sample to Result Innovations
  • Table 4-2: Major Sequencing Platforms
  • Table 4-3: Selected Sequencing-based Innovations, 2012-2013
  • Table 4-4: Diseases with Drug Labels
  • Table 4-5: Selected Drug/Biomarker Targets in the U.S.
  • Table 4-6: Selected Drugs That Recommend PGx Testing in Europe
  • Table 4-7: Selected Cellphone Enabled Test Devices

FIVE: POINT-OF-CARE TESTS

  • Table 5-1: POC Sales by Test Category(Glucose, Glucose continuous, Pregnancy/Ovulation, Coagulation/PT, Fecal Occult Blood, Drugs of abuse, H. pylori, HIV, Cholesterol, Other, Glucose, Critical Care, Pregnancy, Infectious Diseases, Cardiac Markers, Cholesterol/Lipids, Coagulation/PT ACT, HbA1c, Hematology, Fecal occult blood, Drugs of Abuse, Other) , Worldwide 2013-2018
  • Table 5-2: Hospital POC Test Usage (glucose, blood gas/electrolytes, coagulation, urinalysis, co-oximetry, cardiac markers, HbA1c), U.S.
  • Table 5-3: POC Test Revenues of Selected IVD Companies, 2013
  • Table 5-4: World Glucose Monitoring Sales, Major Companies, 2009-2013
  • Table 5-5: Selected Glucose Self-Test Meter Innovations, 2012 and 2013
  • Table 5-6: Selected Apps and Glucose Management IT, 2012 and 2013
  • Table 5-7: Selected Noninvasive Glucose Monitoring Devices
  • Table 5-8: Selected Continuous BGM Sales, 2013
  • Table 5-9: Selected Continuous Blood Glucose System Developments, 2013
  • Table 5-10: Selected Innovations in Hospital-based Glucose Monitoring
  • Table 5-11: Selected POC HbA1c Devices

SIX: THE CORE LAB

  • Table 6-1: Workstation Sales (General Chemistries, Immunos on Workstations), 2013-2018
  • Table 6-2: Core Lab Sales of the Top Five Manufacturers, 2009-2013
  • Table 6-3: Selected New Analytes for the Core Lab, 2012-2013
  • Table 6-4: Selected Lab Automation Innovations, 2012-2013
  • Table 6-5: Worldwide Clinical Chemistry Sales by Test Category (General Chem, Blood Gases, Urinalysis, Critical Care POC) 2013-2018
  • Table 6-6: Major Clinical Chemistry Companies
  • Table 6-7: Major Whole Blood Chemistry Analyzers
  • Table 6-8: Selected Clinical Chemistry Innovations, 2012-2013
  • Table 6-9: Selected Rapid Chemistry Analyzers and Test Innovations, 2012-2013
  • Table 6-10: Selected Apps, Critical Care and Urinalysis Innovations, 2012-2013

SEVEN: IMMUNOASSAYS

  • Table 7-1: Selected Immunoassays on Core Lab Instruments
  • Table 7-2: Selected New Immunoassay Technologies, 2013
  • Figure 7-1: Metabolites as Biomarkers of Disease
  • Table 7-3: Worldwide Lab-based Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D), 2013-2018
  • Table 7-4: Revenue History of Leading Immunoassay Vendors, 2009-2013
  • Table 7-5: Selected Immunoassays Based on Mass Spectrometry
  • Table 7-6: Selected New Vitamin D Immunoassays, 2013
  • Table 7-7: Selected Tumor Marker Innovations, 2013
  • Table 7-8: Selected Cardiac Marker Innovations, 2013
  • Table 7-9: Selected Autoimmune Immunoassay Innovations, 2013
  • Table 7-10: Selected Diabetes Test Innovations, 2013
  • Table 7-11: Selected Women's Health Innovations, 2013
  • Table 7-12: Selected Gastrointestinal Disease Immunoassays, 2013
  • Table 7-13: Selected Immunoassay Innovations, 2013
  • Table 7-14: POC Immunoassay Test Sales by Test Category (OTC/Self Tests, pregnancy/ovulation, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other, Professional Total), 2013-2018
  • Table 7-15: Selected Professional POC Test Innovations, 2013

EIGHT: MOLECULAR ASSAYS

  • Table 8-1: Selected Molecular Test Sample Preparation Innovations, 2013
  • Table 8-2: Selected Exosome Test Innovations
  • Table 8-3: Molecular Test Revenues of Selected IVD Vendors, 2009-2013
  • Table 8-4: Selection Molecular Platform Innovations for Genomic Testing
  • Table 8-5: Worldwide Molecular Test Sales by Type, 2013-2018
  • Table 8-6: Selected Molecular Tumor Marker Test Innovations
  • Table 8-7: Most Frequently Requested Genetic Tests
  • Table 8-8: Selected Genomic Tests for Inherited Diseases, 2013
  • Table 8-9: Selected Molecular Tests for Prenatal Analysis
  • Table 8-10: Selected HLA Typing Test Innovations, 2013
  • Table 8-11: Selected Molecular Test Innovations, 2013

NINE: HEMATOLOGY

  • Table 9-1: Cellavision Placement Data by Hematology Vendor
  • Table 9-2: Selected Hematology Image Analysis Innovations, 2012-2013
  • Table 9-3: Selected POC Hematology Systems
  • Table 9-4: Revenue History of the Major Hematology Vendors 2009-2013
  • Table 9-5: Selected Hematology Innovations, 2012-2013

TEN: COAGULATION

  • Table 10-1: Worldwide Coagulation Sales by Segment (PT/INR - lab, Molecular - lab, POC - professional, POC - self testing), 2013-2018
  • Table 10-2: Selected Coagulation Innovations, 2012-2013
  • Table 10-3: Selected Molecular Coagulation Test Innovations
  • Table 10-4: World POC Coagulation Sales, 2013
  • Table 10-5: Selected Lab-based and POC Coagulation Innovations, 2012-2013
  • Table 10- 6: Selected Platelet Activity Test Innovations, 2012-2013
  • Table 10-7: Top Coagulation Company Revenues 2013 - 2018
  • Table 10-8: Major Anticoagulants Uses and Tests

ELEVEN: MICROBIOLOGY AND VIROLOGY

  • Table 11-1: Selected Tests for Antibiotic Resistance
  • Table 11-2: Selected Microbiology Mass Spec Innovations, 2013
  • Table 11-3: Worldwide Microbiology/Virology Sales by Type (Infectious Diseases - Immunos, Infectious Diseases - Rapid, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies) 2013-2018
  • Table 11-4: Selected Microbiology Media Innovations, 2013
  • Table 11-5: Revenue of Selected Microbiology Companies, 2013
  • Table 11-6: Selected Microbiology ID/AST Innovations, 2013
  • Table 11-7: Selected ID/AST Innovations, 2013
  • Table 11-8: Selected Advanced Techniques for Positive Blood Cultures
  • Table 11-9: Lab-based Infectious Disease Immunoassays, by Test (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others), 2013
  • Table 11-10: Selected Infectious Disease Immunoassay Innovations
  • Table 11-11: Selected Professional-Use POC Tests for Infectious Diseases
  • Table 11-12: Selected Microbiology Sequencing Innovations, 2013
  • Table 11-13: Selected New Instruments for Molecular Infectious Disease Testing, 2013
  • Table 11-14: Molecular Test Sales, Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others), 2013-2018
  • Table 11-15: Selected Molecular HAI Test Innovations, 2013
  • Table 11-16: Selected Molecular STD Innovations, 2013
  • Table 11-17: Selected Molecular Respiratory Disease Innovations, 2013
  • Table 11-18: Selected Molecular HIV Test Innovations, 2013
  • Table 11-19: Selected Molecular POC Device Innovations, 2013
  • Table 11-20: Selected Infectious Disease Molecular Test Innovations

TWELVE: BLOOD BANKING SERVICES

  • Table 12-1: Laboratory Screening of Blood Donations for Transfusion-Transmissible Infections, Number of Countries
  • Table 12-2: Blood Component Usage
  • Table 12-3: Impact of Alloimmunization (% of Patients Screening Positive for One or More Antibodies)
  • Table 12-4: Worldwide Blood Bank Sales, 2013-2018
  • Table 12-5: Selected New Blood Screening Immunoassays, 2012-2013
  • Table 12-6: Selected New Blood Screen NAT Tests and Systems, 2012-2013

THIRTEEN: HISTOLOGY AND CYTOLOGY

  • Table 13-1: Selected Histology Lab Automation, 2013
  • Table 13-2: Selected Advanced Histology Techniques
  • Table 13-3: Selected HPV Test Innovations
  • Table 13-4: Worldwide Histology/Cytology Sales by Type, 2013-2018
  • Table 13-5: Revenues of the Major Histology Companies, 2009-2013
  • Table 13-6: Selected Vendors of Traditional Histology Stains
  • Table 13-7: Selected Molecular Tissue-based Tests, 2013
  • Table 13-8: Selected IHC Test Innovations 2013
  • Table 13-9: Major Pharmacodiagnostic Markers
  • Table 13-10: Selected Pharmacodiagnostic Histology Tests
  • Table 13-11: Selected Digital Imaging Innovations, 2013
  • Table 13-13: Selected Innovations in CTC Technology, 2013
  • Table 13-14: Selected Innovations in Flow Cytometry, 2013
Back to Top